Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October ↗
Sun Pharmaceutical Industries will hold a Board meeting on October 12, 2026, to approve the issuance of non-convertible debentures worth up to ₹15,000 crore to fund a bridge loan for acquiring Organon & Co.
Open on desktop to take part.
0 comments
Comments are posted by users and are not reviewed by Bazaar Updates.
Open on desktop to take part.
Sign in to comment.
No comments yet.